PATENTED PROBIOTIC INGREDIENT
Bacillus coagulans MTCC 5856 by Sabinsa Corporation. FDA GRAS-approved, clinically validated for IBS, immune function, and women's health. No refrigeration required. Available in capsules, tablets, sachets, and powders at Bionial Lifesciences.
UNDERSTANDING LACTOSPORE
LactoSpore is a clinically validated, branded probiotic ingredient containing Bacillus coagulans MTCC 5856, manufactured and patented by Sabinsa Corporation — one of the world's most respected nutraceutical ingredient suppliers. Unlike conventional probiotic strains such as Lactobacillus acidophilus or Bifidobacterium lactis that are fragile, moisture-sensitive, and require continuous cold chain logistics from manufacturing through retail shelf, LactoSpore is a spore-forming bacterium that naturally encapsulates itself in a protective endospore during unfavorable conditions.
This endospore is a biological armour — a multi-layered protein coat that shields the bacterial DNA and metabolic machinery from extremes of heat (up to 85°C), stomach acid (pH as low as 1.5), bile salts, and mechanical compression during tablet manufacturing. When the spore reaches the favorable environment of the small intestine — where warmth, moisture, nutrients, and alkaline pH converge — it germinates into a metabolically active, lactic-acid-producing bacterium within 4 to 6 hours. This germination mechanism ensures near-100% viability at the site of action, a claim that no non-spore-forming Lactobacillus strain can reliably make.
The practical implications for supplement manufacturers and brand owners are transformative. LactoSpore eliminates cold chain requirements entirely. It remains viable at room temperature (25°C / 60% RH) for a minimum of 36 months, survives the tableting compression process that destroys conventional probiotic cells, maintains full potency in zone IV (tropical) storage conditions, and can be combined with ingredients — such as curcumin, iron, or botanical extracts — that would kill standard probiotic strains through oxidative or antimicrobial mechanisms.
LactoSpore (Bacillus coagulans MTCC 5856) is one of the few probiotic strains with GRAS status that remains viable at room temperature for 36+ months, eliminating cold chain requirements.
COMPETITIVE ADVANTAGES
The probiotic supplement market in India is projected to exceed USD 1.2 billion by 2028, yet the majority of probiotic products on retail shelves face a fundamental viability problem. Standard Lactobacillus and Bifidobacterium strains begin dying the moment they are exposed to oxygen, moisture, and heat during manufacturing, and continue to degrade throughout the supply chain. Studies have shown that many commercial probiotic supplements contain less than 10% of the CFU count stated on the label by the time they reach the consumer. LactoSpore solves this problem at the biological level.
LactoSpore spores survive temperatures up to 85°C for extended periods, which means they withstand the heat generated during tablet compression, granulation, and coating processes. Conventional probiotics require expensive overages (manufacturers add 5–10x the label claim at the time of production, knowing most cells will die) and specialized low-temperature manufacturing protocols. With LactoSpore, what you add is what you deliver — the 2 billion CFU per dose at manufacturing is the same 2 billion CFU per dose at 36 months.
The human stomach maintains a pH between 1.5 and 3.5, creating an extremely hostile environment for live bacterial cells. Clinical studies have demonstrated that standard Lactobacillus strains experience 99.9% mortality during gastric transit, which is why many probiotic capsules require enteric coatings that add cost and complexity. Bacillus coagulans MTCC 5856 spores are inherently resistant to this acid environment. Published in vitro studies confirm that LactoSpore maintains greater than 95% viability after 2 hours of exposure to simulated gastric fluid at pH 2.0.
Refrigerated probiotics face constant risk of temperature excursion during shipping, warehousing, and retail display. In India's tropical climate, where ambient temperatures regularly exceed 40°C and humidity surpasses 80% during monsoon months, maintaining cold chain integrity for probiotic supplements is both expensive and unreliable. LactoSpore's accelerated stability data (40°C / 75% RH for 6 months) confirms zero loss of viable spore count under conditions that would eliminate 100% of conventional probiotic populations.
LactoSpore holds FDA GRAS (Generally Recognized As Safe) status, Health Canada NPN (Natural Product Number) approval, and is notified with FSSAI in India. This comprehensive regulatory portfolio provides supplement brands with pre-existing safety documentation that dramatically simplifies product registration. Sabinsa Corporation provides complete dossiers including toxicology reports, genetic characterization, antibiotic resistance profiles, and post-market surveillance data for every lot of LactoSpore supplied.
PUBLISHED CLINICAL RESEARCH
Bacillus coagulans MTCC 5856 is supported by over 25 peer-reviewed clinical studies spanning gastrointestinal health, immune function, women's health, and pediatric wellness.
A landmark randomized, double-blind, placebo-controlled trial published in BMC Gastroenterology demonstrated that LactoSpore at 2 billion CFU/day significantly reduced IBS symptoms including abdominal pain, bloating, incomplete evacuation, and stool inconsistency after 90 days of supplementation. Patients on the LactoSpore arm reported a 40% improvement in composite IBS severity scores compared to 13% in the placebo group. Additional studies confirm efficacy in both IBS-D (diarrhea-predominant) and IBS-M (mixed) subtypes.
Clinical research has demonstrated that Bacillus coagulans MTCC 5856 modulates the immune system by increasing the production of anti-inflammatory cytokines (IL-10) while simultaneously enhancing pro-inflammatory immune surveillance (TNF-alpha, IFN-gamma) against pathogens. A published human trial showed that daily LactoSpore supplementation increased T-cell proliferation, enhanced natural killer cell activity, and reduced the incidence and duration of upper respiratory tract infections during flu season. These immunomodulatory effects are particularly relevant for formulations targeting seasonal immunity and daily wellness.
Emerging clinical research has identified Bacillus coagulans as a beneficial organism for maintaining vaginal microbiome balance. Studies demonstrate that oral supplementation with LactoSpore increases vaginal Lactobacillus populations, normalizes vaginal pH, and reduces the incidence of bacterial vaginosis (BV) recurrence. The mechanism involves LactoSpore's production of lactic acid and bacteriocins that suppress pathogenic organisms while supporting commensal Lactobacilli. This makes LactoSpore an ideal ingredient for women's probiotic formulations combining gut and vaginal health benefits.
Multiple clinical studies confirm LactoSpore's efficacy in preventing and treating both antibiotic-associated diarrhea (AAD) and acute infectious diarrhea. Because Bacillus coagulans spores are inherently resistant to most common antibiotics (including amoxicillin, ciprofloxacin, and metronidazole), LactoSpore can be administered concurrently with antibiotic therapy — a significant advantage over conventional probiotics that are killed by the same antibiotics prescribed to the patient. Clinical data show a 56% reduction in antibiotic-associated diarrhea episodes and faster normalization of stool frequency and consistency.
MANUFACTURING FLEXIBILITY
The spore-forming stability of LactoSpore makes it uniquely compatible with every major supplement dosage form. Our WHO-GMP certified facility in Mohali manufactures LactoSpore products in the following formats.
Vegetarian HPMC and standard gelatin capsules in sizes 00 through 4. Ideal for LactoSpore + prebiotic FOS combinations, multi-strain probiotic blends, and gut-immunity complexes. Available with delayed-release capsule shells for brands requiring additional gastric protection claims.
LactoSpore spores survive the heat and mechanical pressure of tablet compression without viability loss. We manufacture chewable tablets, swallowable tablets, and effervescent tablets incorporating LactoSpore with vitamins, minerals, prebiotics, and digestive enzymes.
Single-dose powder sachets are the preferred format for pediatric probiotic products, travel-friendly gut health supplements, and combination formulas with prebiotics and oral rehydration salts. Our sachets support flavored and unflavored options with precise CFU dosing per unit.
Reconstitutable dry syrups and bulk powder formats for pediatric and geriatric applications. LactoSpore's stability in powder matrices makes it ideal for products intended to be mixed with milk, water, juice, or semi-solid foods. Suitable for custom flavoring and combination with other actives.
PEDIATRIC PROBIOTICS
The pediatric probiotic segment represents one of the fastest-growing categories in the Indian nutraceutical market, driven by increasing awareness among parents and pediatricians about the role of gut microbiome health in childhood immunity, digestive comfort, and even cognitive development. LactoSpore is uniquely suited for pediatric formulations due to its regulatory safety profile, dosing flexibility, and format compatibility.
Bacillus coagulans MTCC 5856 has been evaluated in pediatric clinical studies for infantile colic and acute childhood diarrhea, with positive outcomes in both safety and efficacy parameters. Its GRAS status covers pediatric populations at recommended dosages, providing regulatory confidence for brands launching children's probiotic products.
At Bionial Lifesciences, we offer specialized pediatric LactoSpore formulations in powder sachets and dry syrups with child-friendly flavoring profiles (mango, strawberry, vanilla, orange), precise age-appropriate CFU dosing (typically 1 billion CFU for ages 1–5, 2 billion CFU for ages 6+), and compatibility with common pediatric supplementation vehicles including milk, water, and fruit juice.
READY-TO-MANUFACTURE
These LactoSpore-featuring formulations are ready for immediate manufacturing. Each is backed by Bionial's complete private-label and regulatory support services.
FREQUENTLY ASKED QUESTIONS
LactoSpore is a branded, clinically validated probiotic containing Bacillus coagulans MTCC 5856, a spore-forming bacterium manufactured by Sabinsa Corporation. Unlike regular Lactobacillus strains that are fragile, non-spore-forming organisms requiring refrigeration and special enteric coatings, LactoSpore naturally forms a protective endospore that shields the bacterium from heat, moisture, stomach acid, and bile salts. This means LactoSpore remains viable at room temperature for 36+ months, survives transit through the harsh gastric environment with near-100% viability, and does not require cold chain logistics during shipping or storage.
LactoSpore (Bacillus coagulans MTCC 5856) has been evaluated in over 25 published clinical studies. A landmark randomized, double-blind, placebo-controlled trial published in BMC Gastroenterology demonstrated that LactoSpore at 2 billion CFU per day significantly reduced IBS symptoms including abdominal pain, bloating, diarrhea, and irregular bowel movements after 90 days. Additional studies confirm benefits for antibiotic-associated diarrhea, traveller's diarrhea, and overall digestive comfort. The strain has also shown immunomodulatory activity by increasing beneficial cytokine production.
Yes, LactoSpore holds FDA GRAS (Generally Recognized As Safe) status, which covers both adult and pediatric use at recommended dosages. Clinical studies have evaluated Bacillus coagulans MTCC 5856 in pediatric populations for conditions including infantile colic and acute diarrhea with positive safety and efficacy outcomes. Bionial Lifesciences offers pediatric-specific LactoSpore formulations in powder and sachet formats with age-appropriate dosing, pleasant flavoring, and compatibility with milk, juice, or water for easy administration.
Bionial Lifesciences manufactures LactoSpore probiotic formulations in multiple dosage forms including hard-shell capsules (HPMC vegetarian and gelatin), compressed tablets, powder sachets, and dry syrups. The spore-forming nature of LactoSpore makes it uniquely compatible with manufacturing processes that involve heat, compression, and moisture — conditions that would destroy conventional Lactobacillus strains. This stability allows us to incorporate LactoSpore into combination products alongside vitamins, minerals, prebiotics, and other actives without compromising probiotic viability.
Bionial Lifesciences offers LactoSpore probiotic formulations with a minimum order quantity starting from 1,000 units per SKU. This low MOQ makes our patented probiotic formulations accessible to D2C supplement brands, clinical nutrition companies, and Ayurvedic manufacturers looking to launch premium gut health products. Our standard timeline is 30 days from purchase order to dispatch, and we provide complete private labelling services including FSSAI-compliant label design and branded packaging.
Partner with Bionial Lifesciences for WHO-GMP certified manufacturing of LactoSpore probiotic supplements. Capsules, tablets, sachets, and powders. MOQ from 1,000 units. 30-day delivery.